Diazyme Laboratories Product Pipeline Analysis

SUMMARY

Diazyme Laboratories Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Diazyme Laboratories's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List Of Tables 5
1.2 List of Figures 6
2 Company Overview 7
2.1 Key Information 7
2.2 Financial Performance 7
2.3 Industry Outlook -- In Vitro Diagnostics 7
3 Major Products and Services 8
3.1 Overview 8
4 Competitors 9
5 Key Employees 10
6 Locations And Subsidiaries 11
6.1 Head Office 11
7 Recent Developments 12
7.1 Product News 12
7.1.1 Mar 06, 2008: Diazyme Receives FDA 510(k) Clearance For HDL-Cholesterol Assay 12
7.1.2 Feb 26, 2008: Diazyme Gains FDA Approval For Cystatin C Assay 12
7.2 Product Approvals 12
7.2.1 Mar 06, 2008: Diazyme Receives FDA 510(k) Clearance For HDL-Cholesterol Assay 12
7.2.2 Feb 26, 2008: Diazyme Gains FDA Approval For Cystatin C Assay 12
8 Diazyme Laboratories Pipeline Products 14
8.1 Diazyme Laboratories Product Pipeline Analysis 14
8.1.1 Diazyme Laboratories Pipeline Products By Equipment Type 14
8.1.2 Diazyme Laboratories Pipeline Products By Development Stage 15
8.1.3 Diazyme Laboratories Pipeline Products By Therapy Area 16
8.2 MPO 16
8.2.1 Product Description 16
8.2.2 Product Status 16
8.3 AMACR 17
8.3.1 Product Description 17
8.3.2 Product Status 17
8.4 Triglycerides assay (GPO-PAP) 17
8.4.1 Product Description 17
8.4.2 Product Status 17
8.5 Bilirubin Total assay 18
8.5.1 Product Description 18
8.5.2 Product Status 18
8.6 Lipoprotein Lp(a) immunoturbidimetric 18
8.6.1 Product Description 18
8.6.2 Product Status 19
8.7 Cholesterol assay (CHOD-PAP) 19
8.7.1 Product Description 19
8.7.2 Product Status 19
8.8 Bilirubin Direct assay 19
8.8.1 Product Description 20
8.8.2 Product Status 20
9 Appendix 21
9.1 Methodology 21
9.1.1 Coverage 21
9.1.2 Secondary Research 22
9.1.3 Primary Research 22
9.1.4 Expert Panel Validation 23
9.2 Contact Us 23
9.3 About Global Markets Direct 23
9.4 Disclaimer 23

1.1 List Of Tables
Table 1: Diazyme Laboratories,Key Facts 7
Table 2: Diazyme Laboratories, Key Employees, 10
Table 3: Diazyme Laboratories Pipeline Products by Equipment Type 14
Table 4: Diazyme Laboratories Pipeline Products By Development Stage 15
Table 5: Diazyme Laboratories Pipeline Products By Therapy Area 16

1.2 List of Figures
Figure 1: Diazyme Laboratories Pipeline Products By Development Stage 15
Figure 2: Global Markets Direct Methodology 21